Pharmaceutical industry:Ranbaxy sets up in in the Maghreb

Ranbaxy has incorporated a wholly owned subsidiary in Morocco, Ranbaxy Morocco LLC, in February 2011 with a view to strengthen and grow its business in Morocco. The company was earlier operating in the region through a representative office in Morocco which was set up in 2005.

Ranbaxy is the key supplier of ARVs to the government and numerous products with high potential are under various stages of registration.

With the successful audit of the facility by the Moroccan Health Authorities, Ranbaxy Morocco is now authorized to commence manufacturing of its products at its Casablanca facility. The achievement of this milestone positions Ranbaxy to access a USD 1Billion pharmaceutical market in Morocco.

Commenting on the inauguration of the manufacturing facility at Morocco, Mr. Mahendra Bhardwaj, Head, Africa, Ranbaxy, said, "Ranbaxy has a significant presence in Africa with its own ground operations in key markets. Morocco is one of the important markets and this manufacturing facility further reinforces our commitment to the people of Morocco and the African continent."

In addition to servicing the Morocco market, Ranbaxy also plans to extend the supply from this manufacturing unit to other African countries, in the coming years.

Ranbaxy has a strong presence in Africa. With the addition of Morocco, the Company now has three manufacturing facilities in Africa; the other two located in Nigeria and South Africa respectively. With five subsidiaries, five representative offices and a strong workforce of nearly a 1000 people, Ranbaxy's distribution network caters to 44 of the 54 countries in this continent.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe.